Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (63)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Urwyler, A.
Right arrow Articles by West, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Urwyler, A.
Right arrow Articles by West, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Journal of Anaesthesia, 2001, Vol. 86, No. 2 283-287
© 2001 The Board of Management and Trustees of the British Journal of Anaesthesia

Commentary

Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia{dagger}

A. Urwyler1, T. Deufel2, T. McCarthy3 and S. West4,*

1Departments of Anaesthesia and Research, Kantonsspital, University of Basel, CH-4031 Basel, Switzerland. 2Institute for Clinical Chemistry and Laboratory Diagnosis, University of Jena, D-07743 Jena, Germany. 3Department of Biochemistry, University College Cork, Cork, Republic of Ireland. 4Northern Genetics Service, Molecular Genetics Unit, Newcastle upon Tyne NE2 4AA, UK*Corresponding author

{dagger}This article is accompanied by Editorial III.

Abstract

Malignant hyperthermia (MH) is a potentially fatal pharmacogenetic disease triggered by several anaesthetic agents. The in vitro muscle contracture test (IVCT) is the standard test to establish an individual’s risk of susceptibility to MH. Clinical practitioners and geneticists of the European MH Group have agreed on the present guidelines for the detection of MH susceptibility using molecular genetic techniques and/or IVCT to predict the risk of MH.

Br J Anaesth 2001; 86: 283–7

Footnotes

* for the European Malignant Hyperthermia Group


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
W. Klingler, H. Rueffert, F. Lehmann-Horn, T. Girard, and P. M. Hopkins
Core Myopathies and Risk of Malignant Hyperthermia
Anesth. Analg., October 1, 2009; 109(4): 1167 - 1173.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
P.-L. Chen, Y.-W. Chang, C.-Y. Chen, Y.-C. Hsiang, and Y.-J. Day
Novel Variants Near the Central Domain of RYR1 in Two Malignant Hyperthermia-Susceptible Families from Taiwan
Anesth. Analg., October 1, 2009; 109(4): 1273 - 1277.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
R. Searle and P. M. Hopkins
Pharmacogenomic variability and anaesthesia
Br. J. Anaesth., July 1, 2009; 103(1): 14 - 25.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
M. Broman, A. Gehrig, G. Islander, M. Bodelsson, E. Ranklev-Twetman, H. Ruffert, and C. R. Muller
Mutation screening of the RYR1-cDNA from peripheral B-lymphocytes in 15 Swedish malignant hyperthermia index cases
Br. J. Anaesth., May 1, 2009; 102(5): 642 - 649.
[Abstract] [Full Text] [PDF]

Home page
 Crit Care NurseHome page
K. Anderson-Pompa, A. Foster, L. Parker, L. Wilks, and D. J. Cheek
Genetics and Susceptibility to Malignant Hyperthermia
Crit. Care Nurse, December 1, 2008; 28(6): 32 - 36.
[Full Text] [PDF]

Home page
 Anesth. Analg.Home page
T. Girard, M. Suhner, S. Levano, M. Singer, A. Zollinger, and C. K. Hofer
A Fulminant Malignant Hyperthermia Episode in a Patient with Ryanodine Receptor Gene Mutation p.Tyr522Ser
Anesth. Analg., December 1, 2008; 107(6): 1953 - 1955.
[Abstract] [Full Text] [PDF]

Home page
 Oxford Handbook of AnaesthesiaHome page
K. G. Allman and l. H. Wilson
Malignant hyperthermia
Oxford Handbook of Anaesthesia, January 1, 2006; 2(1): med-9780198566090-div1-10 - med-9780198566090-div1-10.
[Full Text]

Home page
 Anesth. Analg.Home page
H.-M. Yeh, M.-C. Tsai, Y.-N. Su, R.-C. Shen, J.-J. Hwang, W.-Z. Sun, and L.-P. Lai
Denaturing High Performance Liquid Chromatography Screening of Ryanodine Receptor Type 1 Gene in Patients with Malignant Hyperthermia in Taiwan and Identification of a Novel Mutation (Y522C)
Anesth. Analg., November 1, 2005; 101(5): 1401 - 1406.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
M. U. Gerbershagen, M. Fiege, R. Weisshorn, K. Kolodzie, J. S. a. Esch, and F. Wappler
Cumulative and Bolus In Vitro Contracture Testing with 4-Chloro-3-Ethylphenol in Malignant Hyperthermia Positive and Negative Human Skeletal Muscles
Anesth. Analg., September 1, 2005; 101(3): 710 - 714.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
S Shepherd, F Ellis, J Halsall, P Hopkins, and R Robinson
RYR1 mutations in UK central core disease patients: more than just the C-terminal transmembrane region of the RYR1 gene
J. Med. Genet., March 1, 2004; 41(3): e33 - 33.
[Full Text] [PDF]

Home page
 Br J AnaesthHome page
R. R. Johi, R. Mills, P. J. Halsall, and P. M. Hopkins
Anaesthetic management of coronary artery bypass grafting in a patient with central core disease and susceptibility to malignant hyperthermia on statin therapy
Br. J. Anaesth., November 1, 2003; 91(5): 744 - 747.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. Tammaro, A. Bracco, S. Cozzolino, M. Esposito, A. Di Martino, G. Savoia, L. Zeuli, G. Piluso, S. Aurino, and V. Nigro
Scanning for Mutations of the Ryanodine Receptor (RYR1) Gene by Denaturing HPLC: Detection of Three Novel Malignant Hyperthermia Alleles
Clin. Chem., May 1, 2003; 49(5): 761 - 768.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
T. Girard, S. Treves, K. Censier, C. R. Mueller, F. Zorzato, and A. Urwyler
Phenotyping malignant hyperthermia susceptibility by measuring halothane-induced changes in myoplasmic calcium concentration in cultured human skeletal muscle cells
Br. J. Anaesth., October 1, 2002; 89(4): 571 - 579.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
C. Brooks, R. L. Robinson, P. J. Halsall, and P. M. Hopkins
No evidence of mutations in the CACNA1S gene in the UK malignant hyperthermia population{dagger}
Br. J. Anaesth., April 1, 2002; 88(4): 587 - 589.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
C. H. Kindler, T. Girard, D. Gong, and A. Urwyler
The Differential Effect of Halothane and 1,2-Dichlorohexafluorocyclobutane on In VitroMuscle Contractures of Patients Susceptible to Malignant Hyperthermia
Anesth. Analg., April 1, 2002; 94(4): 1028 - 1033.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
R. L. Robinson and P. M. Hopkins
Editorial III: A breakthrough in the genetic diagnosis of malignant hyperthermia
Br. J. Anaesth., February 1, 2001; 86(2): 166 - 168.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.